Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study.
CONCLUSIONS: A number of factors that are predictive of treatment outcomes in a real-life setting were identified. Notably, the decline of treatment benefits may be linked to number of injections and a failure to visit clinicians and receive OCT as required. These findings may be helpful in guiding ophthalmologist treatment decisions under limited time and financial constraints.
TRIAL REGISTRATION NUMBER: NCT01447043.
PMID: 27030279 [PubMed - as supplied by publisher]
Source: The British Journal of Ophthalmology - Category: Opthalmology Authors: Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Hykin P, Staurenghi G, Wittrup-Jensen K, Altemark A, Nilsson J, Kim K, Sivaprasad S Tags: Br J Ophthalmol Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Lucentis | Ophthalmoscopy | Opthalmology | Ranibizumab Injection | Study